WHO Prequalification for GPO’s Efavirenz Production
The World Health Organization (WHO) has officially certified the Government Pharmaceutical Organization’s (GPO) facility in Pathum Thani under the WHO Prequalification Programme (WHO PQ) for the production of the antiretroviral drug Efavirenz. This certification marks a significant milestone as it is the first of its kind in Thailand and the ASEAN region.
Importance of WHO Certification for Efavirenz
GPO director Mingkwan Suphanpong stated that this certification ensures that Efavirenz tablets manufactured by the GPO remain on the WHO Prequalified List. The WHO had previously approved GPO’s request to include Efavirenz on its list in 2018, following an application submitted in 2016.
Role of Efavirenz in HIV Treatment
Efavirenz is a critical medication prescribed to all individuals diagnosed with HIV. It is commonly used in combination with tenofovir/emtricitabine for adults, adolescents, and children. Additionally, it plays a role in post-exposure prophylaxis regimens to reduce the risk of HIV infection among those exposed to significant risk.
Commitment to Quality and Safety
Dr. Mingkwan emphasized that this certification reflects GPO’s dedication to quality and safety, ensuring that Thai citizens have access to effective medications comparable to original formulations. The certification also opens doors for GPO to register the drug in other countries, enhancing export opportunities.
Compliance with WHO Standards
The certification followed a rigorous inspection conducted from August 12-16 last year, assessing compliance with WHO standards regarding manufacturing processes, production support systems, laboratory practices, and quality management. This certification is valid for three years.
Advancements in Generic Drug Production
Dr. Mingkwan highlighted that GPO’s success in producing Efavirenz exemplifies its capabilities in developing generic drugs, particularly essential medicines vital for the healthcare system. Generic medications provide affordable treatment options for Thais while maintaining international credibility.
Future Directions for GPO
To continue benefiting patients after original drug patents expire, Dr. Mingkwan stressed the importance of ongoing research and development of generic drugs by GPO. This proactive approach ensures immediate access to affordable alternatives once patents lapse.
Enhancing Quality of Life for HIV Patients
The recent success of GPO also contributes to improving the quality of life for HIV patients, allowing them to live normal lives akin to non-HIV individuals. According to WHO guidelines, individuals living with HIV who maintain an undetectable viral load pose no risk of transmitting the virus to others.
Advocacy for PLHIV Rights
Jarunee Siriphan, director of the Foundation for Action on Inclusion Rights (Fair), emphasized the significance of the “undetectable equals untransmittable” (U=U) campaign. This public health initiative empowers people living with HIV (PLHIV) by promoting their health and potential without stigma.
Call for Public Health Integration
While acknowledging WHO’s stance on U=U, Jarunee urged the Public Health Ministry to officially certify this approach and integrate it into public policy. She cautioned against employers exploiting this concept by demanding proof of viral suppression during recruitment processes, which could violate individual rights.
A Step Forward in HIV Treatment Accessibility
The WHO certification of GPO’s facility represents a pivotal advancement in Thailand’s efforts to enhance access to effective HIV treatments. By fostering an environment that supports both medical innovation and patient rights, Thailand is making strides towards a healthier future for all individuals living with HIV.
